INTRODUCTION AND OBJECTIVES: Currently, only 30% of patients respond to therapy with checkpoint inhibitors PD-1/PD-L1. Exploration of other members of the B7-CD28 family may provide additional targets for immunotherapy. B7-H4 (VTCN1) has previously been demonstrated to be associated with survival in renal cell carcinoma and breast cancer, but little is known regarding its expression in bladder cancer.
METHODS: Mutational, RNAseq, and clinical data from The Cancer Genome Atlas (TCGA) provisional bladder urothelial carcinoma dataset (n¼408) was downloaded from cBioPortal (http://www.cbio portal.org/). Normalized RNAseq data was correlated with the number of non-synonymous mutations using Spearman's correlation. Overall survival of patients with overexpression (z>2) of immune checkpoints was compared using Kaplan-Meyer analysis. TCGA samples were subtyped using the original TCGA molecular subtypes 1-4 (n¼131). Expression of immune checkpoints was compared between subgroups using ANOVA. Statistical analysis was performed using R and GraphPad Prism.
RESULTS: Overexpression (z>2) of B7-H4 is associated with poor survival (Figure 1 ). Expression of B7-H4 is not associated with expression of CD8A, or with the number of non-synonymous mutations, unlike PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, and LAG-3. Expression of B7-H4 is highest in TCGA subtype II (luminal / p-53-like), unlike PD-1, PD-L1, CTLA-4, TIM-3, and LAG-3 (TCGA subtype IV, basal / claudinlow) (Figure 2) . CONCLUSIONS: Overexpression of B7-H4, a member of the B7-CD28 co-stimulatory family, is associated with poor survival in bladder urothelial carcinoma. B7-H4 is highly expressed in TCGA Subtype II (luminal), unlike PD-L1, which is highly expressed in Subtype IV (basal / claudin-low). Further study of B7-H4 and its function in bladder cancer is needed, but it may be a promising target for immunotherapy, especially for patients who do not respond to PD-L1 therapy. 
MP44-06 IMMUNOHISTOCHEMICAL EVALUATION OF BASAL AND LUMINAL MARKERS IN NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF BLADDER (NMIBC)
Maria Del Carmen Rodriguez Pena*, Aline C Tregnago, Baltimore, MD; Alcides Chaux, Asuncion, Paraguay; Diana Taheri, Walaa Borhan, Baltimore, MD; Katayoon Rezaei, Washington, DC; Marie-Lisa Eich, Hirofumi Nonogaki, Rajni Sharma, George J Netto, Baltimore, MD INTRODUCTION AND OBJECTIVES: The Cancer Genome Atlas (TCGA) collaboration has identified two intrinsic subtypes (basal and luminal) in urothelial bladder carcinoma. However, the study was limited to muscle invasive bladder cancer (MIBC). Subsequent studies suggested a limited panel of immunohistochemical markers could be used to assign basal vs luminal phenotype in MIBC with potential prognostic role. In this study we assess the applicability of the proposed phenotype classification in non-muscle invasive bladder cancer (NMIBC).
METHODS: Three TMAs were constructed from 165 TURB specimens of 52 bladder cancer patients treated at one of author's institution (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . Follow up data on recurrence, grade or stage progression were obtained. Immunohistochemistry was performed using automated Ventana System for markers indicative of luminal (GATA3, CK20, ER, uroplakin, HER2/neu) and basal phenotype (CK5/6 and CD44). The extent, intensity and pattern of expression were evaluated for all markers by 3 urologic pathologists. HER2/neu was assessed using the breast and stomach scoring systems.
RESULTS: By univariate analysis, using mean extent of expression as a cut off, higher proportion (83%; p¼0.002) of tumors with stage progression demonstrated high CK5/6 expression. 15/143 (10.4%) of tumors with high CK5/6 expression demonstrated a higher stage on subsequent biopsy compared to 3/176 (1.7%) of those with low CK5/6. Higher proportion of tumors with stage progression had low levels of CK20 (75%;p¼0.03) and CD44 (66%;p¼0.009). Regarding recurrence, higher proportion of tumors with recurrence had low Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e565
